Anna Sitthi-Amorn - Janssen Res & Dev LLC

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 11 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in (D-Vrd) Transplant-Eligible (TE) Patients with Newly Diagnosed Multiple Myeloma (NDMM): Analysis of Minimal Residual Disease (MRD) in the Phase 3 PERSEUS Study

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2024): S550-S551

Cited0Views0Bibtex

A Plain Language Summary of the PERSEUS Study of Daratumumab Plus Bortezomib, Lenalidomide, and Dexamethasone for Treating Newly Diagnosed Multiple Myeloma

Future Oncologypp.1-21, (2024)

Cited0Views0WOSBibtex

P-368 Stem Cell (SC) Yield and Transplant with Daratumumab ± Bortezomib, Lenalidomide and Dexamethasone in Transplant-eligible Newly Diagnosed Multiple Myeloma Patients in the Phase 3 PERSEUS Study

Pieter Sonneveld,Meletios Dimopoulos,Mario Boccadoro,Hang Quach, P. Joy Ho,Meral Beksac,Cyrille Hulin, Elisabetta Antonioli,Xavier Leleu,Silvia Mangiacavalli, Aurore Perrot,Michele Cavo,Angelo Belotti,Annemiek Broijl,Francesca Gay, Roberto Mina,Niels van de Donk,Yanfang Liu, Jianping Wang,Anna Sitthi-Amorn

Clinical Lymphoma Myeloma and Leukemia (2024): S246

Cited0Views0Bibtex

Daratumumab + Bortezomib/Lenalidomide/Dexamethasone (D-Vrd) in Transplant-Eligible (TE) Patients with Newly Diagnosed Myeloma (NDMM): Analysis of the Phase 3 PERSEUS Study Based on High-Risk Cytogenetic Abnormalities (Hrcas)

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2024): S547-S548

Cited0Views0Bibtex

Bloodno. Supplement 1 (2024): 2000-2000

Cited0Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn